Novel ocular antihypertensive compounds in clinical trials

Abstract

Introduction:Glaucoma is a multifactorial disease characterized by progressive optic nerve injury and visual field defects. Elevated intraocular pressure (IOP) is the most widely recognized risk factor for the onset and progression of open-angle glaucoma, and IOP-lowering medications comprise the primary treatment strategy. IOP elevation in glaucoma is associated with diminished or obstructed aqueous humor outflow. Pharmacotherapy reduces IOP by suppressing aqueous inflow and/or increasing aqueous outflow.Purpose:This review focuses on novel non-FDA approved ocular antihypertensive compounds being investigated for IOP reduction in ocular hypertensive and glaucoma patients in active clinical trials within approximately the past 2 years.Methods:The mode of IOP reduction, pharmacology, efficacy, and safety of these new agents were assessed. Relevant drug efficacy and safety trials were identified from searches of various scientific literature databases and clinical trial registries. Compounds with no specified drug class, insufficient background information, reformulations, and fixed-combinations of marketed drugs were not considered.Results:The investigational agents identified comprise those that act on the same targets of established drug classes approved by the FDA (ie, prostaglandin analogs and β-adrenergic blockers) as well as agents belonging to novel drug classes with unique mechanisms of action. Novel targets and compounds evaluated in clinical trials include an actin polymerization inhibitor (ie, latrunculin), Rho-associated protein kinase inhibitors, adenosine receptor analogs, an angiotensin II type 1 receptor antagonist, cannabinoid receptor agonists, and a serotonin receptor antagonist.Conclusion:The clinical value of novel compounds for the treatment of glaucoma will depend ultimately on demonstrating favorable efficacy and benefit-to-risk ratios relative to currently approved prostaglandin analogs and β-blockers and/or having complementary modes of action.

The Microfibril Hypothesis of Glaucoma: Implications for Treatment of Elevated Intraocular Pressure

“…However, the company discontinued an early phase II clinical trial reporting only a small reduction of IOP without a clear dose-response relationship. 117 In the Marfan mouse model, selective inhibition of AT1 with losartan more effectively prevented thickening of the aortic wall than did inhibition of both AT1 and AT2 with ACE inhibitors (Fig. 3), even though ACE inhibitors were more effective in reducing TGFb signaling.…”

Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway

“…Receptor activation has also been shown to induce the secretion of MMPs, particularly MMP-2, probably the cause of reduced outflow resistance [167,168]. Increases in facility were negated by the addition of an MMP inhibitor, implicating ECM remodeling along with cell volume shrinkage as mediators of outflow enhancement [169,170].…”

Emerging Trends in Ocular Drug Delivery: A Review on Recent Updates

“…Phase 2 clinical studies demonstrated the efficacy and safety in subjects with open angle glaucoma and ocular hypertension [21]. Intracanalicular inserts loaded with travoprost is being developed by ocular therapeutix for the treatment of glaucoma and ocular hypertension.…”